AstraZeneca taps new chairman; Pfizer drops menopause pitch for Pristiq; New target for cancer drug?

@FierceBiotech: AstraZeneca's FluMist Quadrivalent #vaccine to hit U.S. market. Story | Follow @FierceBiotech

 @JohnCFierce: Smart: Keep Kelly Martin as CEO at Elan until bapineuzumab data comes in. New guy can pick up the pieces; or Martin ends up unlikely hero. | Follow @JohnCFierce

@RyanMFierce: Eli Lilly has trotted out a $10M program with academic partners that has long odds of bringing the company any new drugs. More | Follow @RyanMFierce

@MarkHFierce: Math + genetics + health data helps Utah doctors customize blood thinner dosing. Surprisingly practical. Story | Follow @MarkHFierce

> AstraZeneca ($AZN) has turned to the telecom industry for its next chairman. Leif Johansson, the chairman of Ericsson, will take the spot occupied by Louis Schweitzer. Johansson had been on the board at Bristol-Myers Squibb ($BMY) for 13 years before stepping down last fall. Story

> Pfizer ($PFE) has dropped its effort to expand the approved use of Pristiq, a depression treatment, for menopause-related symptoms. Report

> AltheRx Pharmaceuticals has presented positive results from its Phase II study of Solabegron in overactive bladder. Release

Pharma News

@FiercePharma: Greece austerity deal includes mandated generics, drug-spending limits--Reuters. Article | Follow @FiercePharma

> Pharma group adopts stringent conduct code. News

> GSK, Daiichi team to develop, launch vaccines in Japan. Story

> EC antitrust squad drops AZ-Nycomed probe. Article

Vaccines News

> Universal vaccine could cut flu across the whole community. Report

> Inactivated polio vaccine reaches Nigeria. More

> Bacteria may lead to HIV vaccine. Article

> Getting under the skin of vaccines. Story

> Cell-based pancreatic cancer vaccine increases survival. News

Manufacturing News

> IT issues at Biochem lab raise data integrity concerns. Article

> Industry faces having to fund drug-disposal program. Story

> FDA puts burning questions to Fukuda Denshi about device. More

> Abbott banks on boomers with $270M nutrition facility. Item

CRO News

> Newsummit Biopharma's $80M IPO reflects CRO surge in China. More

> Icon snatches up drug pricing guru PriceSpective. Article

> Quintiles partners with Russians on new drug development ventures. News

> Feds say contract testing lab's protocols damaged data integrity. Story

And Finally… Researchers at the University of Illinois at Chicago College of Medicine say they have a new cancer drug target. They believe that a molecule found at elevated levels in cancer cells protects them from the "cell-suicide," or apoptosis, that is usually triggered by chemotherapy or radiation. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.